Article citationsMore >>

Zhang, X, Zheng, W, Wang, T, Ren, P, Wang, F, Ma, X, Wang, J, Huang, X. “Danshen-Chuanxiong-Honghua Ameliorates Cerebral Impairment and Improves Spatial Cognitive Deficits after Transient Focal Ischemia and Identification of Active Compounds,” Frontiers in Pharmacology, 8(452). Jul. 2017 [Online] Available: https://www.frontiersin.org/articles/10.3389/fphar.2017.00452/full.

has been cited by the following article:

Article

Treatment of Postmenopausal Syndrome with UBPN01: A Randomized, Double-blind, Placebo-controlled Study

1Department of Oriental Medicine and Biotechnology, Kyung Hee University, Giheung-gu, Yongin 17104, Republic of Korea

2ResearchMentor, 909 SK V1 tower #905, Yeonmujang 5 ga-gil 25, Seongdong-gu, Seoul 04782, Republic of Korea

3Santosh Hospital. 6/1, Promenade Road, near Coles park, Bengaluru 560005, India

4Vagus Super Specialty Hospital, #6-8 18th Cross, Malleshwaram, Bengaluru 560003, India

5UNDBIO Co., Ltd. #1101, 91, Changnyong-daero 256 beon-gil 77, Suwon 16229, Republic of Korea


Journal of Food and Nutrition Research. 2022, Vol. 10 No. 7, 496-502
DOI: 10.12691/jfnr-10-7-8
Copyright © 2022 Science and Education Publishing

Cite this paper:
Jeong Eun Kwon, Yeong-Geun Lee, Tae Hee Kim, Gyoungok Gang, Gokce Altun, Farzana Mushtaq Ahmed, Narayanaswamy Venkatappa, Hyukjin Kwon, Jihyeong Park, Se Chan Kang. Treatment of Postmenopausal Syndrome with UBPN01: A Randomized, Double-blind, Placebo-controlled Study. Journal of Food and Nutrition Research. 2022; 10(7):496-502. doi: 10.12691/jfnr-10-7-8.

Correspondence to: Se  Chan Kang, Department of Oriental Medicine and Biotechnology, Kyung Hee University, Giheung-gu, Yongin 17104, Republic of Korea. Email: sckang@khu.ac.kr

Abstract

This study evaluated the efficacy of UBPN01 (Salvia miltiorrhiza extract) for alleviating menopausal syndrome. This study was a randomized, double-blind, placebo-controlled clinical trial involving female subjects (40 – 60 years) with menopausal syndrome. Subjects were administered 600 mg/day UBPN01 or placebo, and efficacy endpoints were menopausal symptoms according to the total Kupperman Index (KI) score and individual categories. After 12 weeks, the total KI scores decreased and depression and vaginal dryness symptoms improved, especially in UBPN01 compared to placebo. Moreover, we observed no significant difference between the two groups in estradiol, follicle stimulating hormone, or luteinizing hormone. These results demonstrated that UBPN01 alleviates menopausal symptoms without notable side effects and improves quality of life, suggesting its efficacy as an alternative supplement for women ineligible for hormone therapy.

Keywords